Obstructive Sleep ApneaNCT02159885
Telemedici ne Management of Veterans With Newly Diagnosed Obstructiv e Sleep Apnea (OSA)
A study testing Telemonitoring in people with Obstructive Sleep Apnea, run by Corporal Michael J. Crescenz VA Medical Center at 1 site in United States.
Trial summary
Automatically titrating continuous positive airway pressure (APAP) and continuous positive airway pressure (CPAP) are considered first-line treatments for obstructive sleep apnea. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Obstructive Sleep Apnea
- What is being tested?
- Telemonitoring
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 53 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 2014to Jul 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male and female veterans at least 18 years of age.
- Ability to read and speak English (assessment instruments and therapy will be available only in English).
- AHI> 5 on baseline home sleep study
- Agree to initiate automatically titrating continuous positive airway pressure (APAP) therapy.
- Completion of clinic questionnaires during initial sleep evaluation
Who cannot join
- Unwilling to provide informed consent.
- Lack of English fluency. This will be determined when potential subjects are contacted by phone. If they are able to understand the oral consent by correctly completing the mini-quiz, English fluency will be established.
- No telephone access
- Patients previously treated with positive airway pressure.
- Patients enrolled in ongoing VA sleep research studies. Currently all patients enrolled in VA sleep research studies already have their charts flagged.
- Patients receiving their sleep care at VA medical centers other than PVAMC, Fort Dix, Gloucester and Victor J. Saracini (Willow Grove).
- Patients initiated on positive airway pressure treatment while in-patients will also be excluded.
- Patients who are set up with APAP machines without modems will also be excluded.
Trial locations and contacts
1 site in 1 country.
About this study
Automatically titrating continuous positive airway pressure (APAP) and continuous positive airway pressure (CPAP) are considered first-line treatments for obstructive sleep apnea. There is a growing body of evidence that suggests that early patient education and intervention may improve adherence with positive airway pressure. The investigators plan a prospective, randomized trial to see if telemonitoring in the first several weeks of PAP therapy improves adherence following 3 months of treatment.
Read the detailed description
Obstructive sleep apnea is a high-priority clinical condition for the Veterans Health Administration. With approximately 2% of middle-aged women and 4% of middle-aged men having OSA, the disorder places significant burden on the healthcare system. Obstructive sleep apnea (OSA) has been linked to major cardiovascular disorders such as coronary artery disease, congestive heart failure, hypertension, and stroke, as well as increased risk for motor vehicle crashes. Positive airway pressure (PAP) therapy is considered the treatment of choice for obstructive sleep apnea. However, adherence rates with CPAP and APAP therapy are disappointingly low. Veterans, especially those who are socioeconomically disadvantaged and those with psychiatric disease, demonstrate poor adherence when compared to the general population. Effective interventions are needed to improve adherence among patients diagnosed with OSA.
Currently, veterans diagnosed with OSA at the Philadelphia VA sleep center are treated with a home APAP machine that records their adherence on a smart card. They are scheduled for a follow-up appointment within one to three months after their initiation of APAP therapy to discuss questions and concerns regarding the machine as well as the mask and to download their adherence data. Given the limited availability of clinic appointments, some patients may have to wait longer than this.
More recently, APAP machines now distributed through the VA system offer the possibility of using wireless transmissions to track adherence data, including hours of use, mask leak, and apnea-hypopnea index (this transmission does not require hook up to the telephone and does not require the patient to have internet access). This offers the opportunity to see if remote monitoring within the first several weeks of APAP treatment improves adherence, and in turn, improves clinical response to treatment. At the present time, all patients enrolled at Philadelphia Veterans Administration Medical Center (PVAMC) who are newly diagnosed with OSA are being provided with APAP machines with modems that allow for wireless transmissions of data through the Phillips Respironics HIPPA compliant website, www.encoreanywhere.com. Review of the modem data is being performed on a limited basis in some patients. If remote monitoring improves adherence, the investigators may want to implement it for all APAP users. At present, the investigators do not know if this is a clinically effective or cost effective model for delivering health care.
The investigators will have a baseline chart review. It will include assessment of APAP settings (auto-titrate pressure ranges), model and size of mask interface, baseline sleep study results (mean AHI), and review of surveys now obtained as part of routine clinical care at the investigators sleep center, including: Epworth Sleepiness Scale (ESS) score, functional outcomes of sleep questionnaire (FOSQ) score, center for epidemiological studies of depression scale (CES-D score), short form health survey (SF-12), a health survey score and client satisfaction questionnaire (CSQ-8).
Sleep center staff will also perform a chart review to obtain demographic information (age, sex, race), BMI, daytime oxygen saturation (if available), and co-morbidities (congestive heart failure, diabetes, hypertension, obesity, chronic obstructive pulmonary disease (COPD), and depression or other psychological disorders) as part of their problem list in the computerized VA medical record. the investigators will use this chart review to compute a Charlson Morbidity Index.
The investigators then plan to randomize 126 patients to either usual care or usual care in addition to telemonitoring.
Standard of Care Arm: Patients assigned to receive standard of care will be set-up with an APAP machine through Eagle Home Medical, our contracted local home health care agency. Patients will also receive the sleep staff's phone number should they encounter problems with the use of their new equipment. Patients will be scheduled to see a sleep practitioner within one to three months of the initiation of APAP therapy.
At the follow-up office visit, practitioners will assess mask leak, mean daily APAP usage, AHI through either secure digital (SD) cards or Encore Anywhere. Practitioners will also calculate the patient's ESS score and inquire about frequent complications associated with APAP-usage, such as dry mouth and mask discomfort.
After three months of treatment, all patients in the usual care arm will also have their EncoreAnywhere data reviewed. They will receive a phone call from our sleep center staff to assess their experience with their APAP machines. If patients have not had a follow-up clinic visit, they will be scheduled for one. In addition, all subjects will be mailed survey to reassess their functional outcomes including: ESS score, FOSQ- 10, another subjective measurement of sleepiness, the CES-D score, an assessment of depression symptoms, the CSQ-8, an assessment of patient satisfaction, and the SF-12 health survey, an assessment of health.
Telemonitoring Arm: Patients will be set-up with an APAP machine through Eagle Home Medical, our contracted local home health care agency. Patients will also receive the sleep staff's phone number should they encounter problems with the use of their new equipment. Patients will be scheduled to see a sleep practitioner within one to three months of the initiation of APAP therapy. At that follow-up appointment, APAP settings, APAP adherence, mask comfort, humidifier usage, and ESS score will be assessed.
In addition, patients in the telemonitoring arm will have their adherence data monitored by sleep research staff. Patients who demonstrate poor adherence will receive phone calls at scheduled intervals (Day 2, Day 9, and Day 16). Poor adherence is defined as a large mask leak for 30% of the night, 30% or more of days with less than 4 hours of use, or an AHI > 10 events/hr.
Day 2 (Can call up to 120 hours after initiation of treatment) Two days after initiation of APAP data, intervention arm patients will have their data reviewed by the sleep study staff. Patients will receive a follow-up call if any of the following are present: large mask leak, 30% or more of days with less than 4 hours of use, or machine measured average AHI > 10 events/hr. Patients will be assessed for symptoms such as dry mouth, mask issues, or discomfort with the device, or any other problems. Interventions to improve adherence (i.e.: a different mask, chin strap, modifications of pressure settings, modifications of humidifier settings, saline nasal sprays) will then be prescribed if needed. Patients will also be given the sleep center number if they have questions regarding the use of their equipment.
Day 9: (Can call up to 120 hours after Day 9) Patients in the intervention arm will have their data reviewed again. They will receive a follow-up call if poor adherence is noted. Symptoms will be assessed and interventions to improve adherence will be offered.
Day 16: (Can call up to120 hours after Day 16) Patients in the intervention are will have their data reviewed again and called if poor adherence and/or efficacy is noted. Symptoms will be assessed and interventions to improve adherence will be offered.
Three Month Follow-up: All patients will have their EncoreAnywhere data reviewed. If patients have not had a follow-up visit within one to three months of APAP set-up, they will be scheduled for one. Surveys will be mailed to all subjects to reassess functional outcomes, including: ESS, FOSQ, CES-D, SF-12 health survey, and CSQ-8.
- Conditions
- Obstructive Sleep Apnea
- Being tested
- Telemonitoring
- Keywords
- obstructive sleep apnea, adherence, telemedicine, auto-titrating continuous positive airway pressure
- Medical subject headings
- Sleep Apnea, Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TelemonitoringOther
| Study group | Role | What they receive |
|---|---|---|
| Telemonitoring | Experimental | In this arm, subjects will receive usual care at the sleep clinic as well as telemonitoring of their use of their automatically adjusting continuous positive airway pressure pressure (APAP) machine. They will receiving phone calls for poor adherence and/or poor efficacy of treatment. Receives: Other: Telemonitoring |
| Usual Care | No intervention | Subjects in this arm will receive "usual care" for management of obstructive sleep apnea and use of automatically titrating continuous positive airway pressure. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Average daily hours of APAP use
Aim 1: The goal of this project is to determine whether telemedicine monitoring of APAP treatment in the first several weeks of treatment improves adherence following 3 months of treatment. Adherence will be measured objectively by the average daily hours of APAP use over 90 days.
Measured: 90 days
Secondary outcomes (1)
Change in FOSQ-10 score
A secondary goal is determine if telemonitoring of APAP treatment improves functional outcomes. We will assess the change in Functional Outcomes Sleep Questionnaire (our primary functional outcome FOSQ- 10), a disease specific quality of life questionnaire.
Measured: Change in baseline FOSQ-10 score to the FOSQ-10 score assessed at 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2014 (estimated)
- Study startApr 2014
- Primary completionJul 2016
- Study completionJul 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obstructive Sleep ApneaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 53 participants (actual)
Sponsor and investigators
- Lead sponsor
- Corporal Michael J. Crescenz VA Medical Center
- Sponsor type
- US federal agency
- Responsible party
- Sponsor
- Investigators
- Samuel Kuna, MD, Principal investigator, Philadelphia VAMC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02159885
- Sponsor's protocol ID
- 01473
- Status last verified
- Aug 2016
- First submitted
- 28 Apr 2014
- Last updated
- 10 Aug 2016
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Telemedici ne Management of Veterans With Newly Diagnosed Obstructiv e Sleep Apnea (OSA)
- ClinicalTrials.gov ID
- NCT02159885
- Acronym / sponsor ID
- 01473
- Conditions
- Obstructive Sleep Apnea
- Keywords
- obstructive sleep apnea, adherence, telemedicine, auto-titrating continuous positive airway pressure
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 53 participants (actual)
- Lead sponsor
- Corporal Michael J. Crescenz VA Medical CenterUS federal agency
- Study start
- Apr 2014
- Primary completion
- Jul 2016 (actual)
- Study completion
- Jul 2016 (actual)
- First posted
- 10 Jun 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Automatically titrating continuous positive airway pressure (APAP) and continuous positive airway pressure (CPAP) are considered first-line treatments for obstructive sleep apnea. There is a growing body of evidence that suggests that early patient education and intervention may improve adherence with positive airway pressure. The investigators plan a prospective, randomized trial to see if telemonitoring in the first several weeks of PAP therapy improves adherence following 3 months of treatment.
Detailed description
Obstructive sleep apnea is a high-priority clinical condition for the Veterans Health Administration. With approximately 2% of middle-aged women and 4% of middle-aged men having OSA, the disorder places significant burden on the healthcare system. Obstructive sleep apnea (OSA) has been linked to major cardiovascular disorders such as coronary artery disease, congestive heart failure, hypertension, and stroke, as well as increased risk for motor vehicle crashes. Positive airway pressure (PAP) therapy is considered the treatment of choice for obstructive sleep apnea. However, adherence rates with CPAP and APAP therapy are disappointingly low. Veterans, especially those who are socioeconomically disadvantaged and those with psychiatric disease, demonstrate poor adherence when compared to the general population. Effective interventions are needed to improve adherence among patients diagnosed with OSA.
Currently, veterans diagnosed with OSA at the Philadelphia VA sleep center are treated with a home APAP machine that records their adherence on a smart card. They are scheduled for a follow-up appointment within one to three months after their initiation of APAP therapy to discuss questions and concerns regarding the machine as well as the mask and to download their adherence data. Given the limited availability of clinic appointments, some patients may have to wait longer than this.
More recently, APAP machines now distributed through the VA system offer the possibility of using wireless transmissions to track adherence data, including hours of use, mask leak, and apnea-hypopnea index (this transmission does not require hook up to the telephone and does not require the patient to have internet access). This offers the opportunity to see if remote monitoring within the first several weeks of APAP treatment improves adherence, and in turn, improves clinical response to treatment. At the present time, all patients enrolled at Philadelphia Veterans Administration Medical Center (PVAMC) who are newly diagnosed with OSA are being provided with APAP machines with modems that allow for wireless transmissions of data through the Phillips Respironics HIPPA compliant website, www.encoreanywhere.com. Review of the modem data is being performed on a limited basis in some patients. If remote monitoring improves adherence, the investigators may want to implement it for all APAP users. At present, the investigators do not know if this is a clinically effective or cost effective model for delivering health care.
The investigators will have a baseline chart review. It will include assessment of APAP settings (auto-titrate pressure ranges), model and size of mask interface, baseline sleep study results (mean AHI), and review of surveys now obtained as part of routine clinical care at the investigators sleep center, including: Epworth Sleepiness Scale (ESS) score, functional outcomes of sleep questionnaire (FOSQ) score, center for epidemiological studies of depression scale (CES-D score), short form health survey (SF-12), a health survey score and client satisfaction questionnaire (CSQ-8).
Sleep center staff will also perform a chart review to obtain demographic information (age, sex, race), BMI, daytime oxygen saturation (if available), and co-morbidities (congestive heart failure, diabetes, hypertension, obesity, chronic obstructive pulmonary disease (COPD), and depression or other psychological disorders) as part of their problem list in the computerized VA medical record. the investigators will use this chart review to compute a Charlson Morbidity Index.
The investigators then plan to randomize 126 patients to either usual care or usual care in addition to telemonitoring.
Standard of Care Arm: Patients assigned to receive standard of care will be set-up with an APAP machine through Eagle Home Medical, our contracted local home health care agency. Patients will also receive the sleep staff's phone number should they encounter problems with the use of their new equipment. Patients will be scheduled to see a sleep practitioner within one to three months of the initiation of APAP therapy.
At the follow-up office visit, practitioners will assess mask leak, mean daily APAP usage, AHI through either secure digital (SD) cards or Encore Anywhere. Practitioners will also calculate the patient's ESS score and inquire about frequent complications associated with APAP-usage, such as dry mouth and mask discomfort.
After three months of treatment, all patients in the usual care arm will also have their EncoreAnywhere data reviewed. They will receive a phone call from our sleep center staff to assess their experience with their APAP machines. If patients have not had a follow-up clinic visit, they will be scheduled for one. In addition, all subjects will be mailed survey to reassess their functional outcomes including: ESS score, FOSQ- 10, another subjective measurement of sleepiness, the CES-D score, an assessment of depression symptoms, the CSQ-8, an assessment of patient satisfaction, and the SF-12 health survey, an assessment of health.
Telemonitoring Arm: Patients will be set-up with an APAP machine through Eagle Home Medical, our contracted local home health care agency. Patients will also receive the sleep staff's phone number should they encounter problems with the use of their new equipment. Patients will be scheduled to see a sleep practitioner within one to three months of the initiation of APAP therapy. At that follow-up appointment, APAP settings, APAP adherence, mask comfort, humidifier usage, and ESS score will be assessed.
In addition, patients in the telemonitoring arm will have their adherence data monitored by sleep research staff. Patients who demonstrate poor adherence will receive phone calls at scheduled intervals (Day 2, Day 9, and Day 16). Poor adherence is defined as a large mask leak for 30% of the night, 30% or more of days with less than 4 hours of use, or an AHI > 10 events/hr.
Day 2 (Can call up to 120 hours after initiation of treatment) Two days after initiation of APAP data, intervention arm patients will have their data reviewed by the sleep study staff. Patients will receive a follow-up call if any of the following are present: large mask leak, 30% or more of days with less than 4 hours of use, or machine measured average AHI > 10 events/hr. Patients will be assessed for symptoms such as dry mouth, mask issues, or discomfort with the device, or any other problems. Interventions to improve adherence (i.e.: a different mask, chin strap, modifications of pressure settings, modifications of humidifier settings, saline nasal sprays) will then be prescribed if needed. Patients will also be given the sleep center number if they have questions regarding the use of their equipment.
Day 9: (Can call up to 120 hours after Day 9) Patients in the intervention arm will have their data reviewed again. They will receive a follow-up call if poor adherence is noted. Symptoms will be assessed and interventions to improve adherence will be offered.
Day 16: (Can call up to120 hours after Day 16) Patients in the intervention are will have their data reviewed again and called if poor adherence and/or efficacy is noted. Symptoms will be assessed and interventions to improve adherence will be offered.
Three Month Follow-up: All patients will have their EncoreAnywhere data reviewed. If patients have not had a follow-up visit within one to three months of APAP set-up, they will be scheduled for one. Surveys will be mailed to all subjects to reassess functional outcomes, including: ESS, FOSQ, CES-D, SF-12 health survey, and CSQ-8.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Telemonitoring | Experimental | Other: TelemonitoringIn this arm, subjects will receive usual care at the sleep clinic as well as telemonitoring of their use of their automatically adjusting continuous positive airway pressure pressure (APAP) machine. They will receiving phone calls for poor adherence and/or poor efficacy of treatment. |
| Usual Care | No intervention | –Subjects in this arm will receive "usual care" for management of obstructive sleep apnea and use of automatically titrating continuous positive airway pressure. |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Male and female veterans at least 18 years of age.
- Ability to read and speak English (assessment instruments and therapy will be available only in English).
- AHI> 5 on baseline home sleep study
- Agree to initiate automatically titrating continuous positive airway pressure (APAP) therapy.
- Completion of clinic questionnaires during initial sleep evaluation
Key exclusion criteria (8 listed)
- Unwilling to provide informed consent.
- Lack of English fluency. This will be determined when potential subjects are contacted by phone. If they are able to understand the oral consent by correctly completing the mini-quiz, English fluency will be established.
- No telephone access
- Patients previously treated with positive airway pressure.
- Patients enrolled in ongoing VA sleep research studies. Currently all patients enrolled in VA sleep research studies already have their charts flagged.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Telemonitoring | Other | Telemonitoring |
Primary outcome
Average daily hours of APAP use
Time frame: 90 days
Aim 1: The goal of this project is to determine whether telemedicine monitoring of APAP treatment in the first several weeks of treatment improves adherence following 3 months of treatment. Adherence will be measured objectively by the average daily hours of APAP use over 90 days.
1 secondary outcome
Change in FOSQ-10 score
Time frame: Change in baseline FOSQ-10 score to the FOSQ-10 score assessed at 90 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2016.
Related trials for Obstructive Sleep Apnea
RecruitingObservational study
Development and Validation of a Multimodal Deep Learning Model Using Peripheral Oxygen Saturation and Ballistocardiography Signals for Predicting Apnea-Hypopnea Index in Obstructive Sleep Apnea
Obstructive Sleep Apnea
RecruitingPhase 3
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)
Apnea, Sleep Disorders
Not yet recruitingPhase 2
Supplemental Oxygen for Sleep-Disordered Breathing in Adults With Chronic Opioid Use.
Sleep-disordered Breathing, Chronic Opioid Use
Recruiting
Nightly Wearable Monitoring During Home-Based Submental Electrical Stimulation for Obstructive Sleep Apnea
Obstructive Sleep Apnea
RecruitingPhase 1/2
DRonabinol Treatment of OSA
Obstructive Sleep Apnea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Samuel Kuna, MD principal investigator
Philadelphia VAMC
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Telemonitoring in people with Obstructive Sleep Apnea, run by Corporal Michael J. Crescenz VA Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Aug 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Average daily hours of APAP use (time frame: 90 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2016.